Search Results - "Saletti, P."

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients by FRATTINI, M, SALETTI, P, ROMAGNANI, E, MARTIN, V, MOLINARI, F, GHISLETTA, M, CAMPONOVO, A, ETIENNE, L. L, CAVALLI, F, MAZZUCCHELLI, L

“…To evaluate whether the epidermal growth factor receptor (EGFR), K-Ras and PTEN, all members of the EGFR signalling pathway, may affect the clinical response…”
Get full text

Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29) by Koeberle, D., Dufour, J.-F., Demeter, G., Li, Q., Ribi, K., Samaras, P., Saletti, P., Roth, A.D., Horber, D., Buehlmann, M., Wagner, A.D., Montemurro, M., Lakatos, G., Feilchenfeldt, J., Peck-Radosavljevic, M., Rauch, D., Tschanz, B., Bodoky, G.

“…Sorafenib (S), a multitargeted tyrosine kinase inhibitor, is the standard of care for first-line systemic treatment of advanced hepatocellular carcinoma (HCC)…”
Get full text

HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients by Martin, V, Landi, L, Molinari, F, Fountzilas, G, Geva, R, Riva, A, Saletti, P, De Dosso, S, Spitale, A, Tejpar, S, Kalogeras, K T, Mazzucchelli, L, Frattini, M, Cappuzzo, F

“…Background: In metastatic colorectal cancer (mCRC), KRAS is the only validated biomarker used to select patients for administration of epidermal growth factor…”
Get full text

Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06) by Koeberle, D., Betticher, D.C., von Moos, R., Dietrich, D., Brauchli, P., Baertschi, D., Matter, K., Winterhalder, R., Borner, M., Anchisi, S., Moosmann, P., Kollar, A., Saletti, P., Roth, A., Frueh, M., Kueng, M., Popescu, R.A., Schacher, S., Hess, V., Herrmann, R.

“…In this trial, stopping bevacizumab after completion of induction chemotherapy was associated with a shorter time to progression, but no statistically…”
Get full text

Lymphocyte count and lymphocyte-to-white blood cells ratio as indicators of survival in specific cancer subtypes by Cefalì, M., Efstathopoulou, A., De Dosso, S., Saletti, P.

“…•Inflammation-related blood parameters have prognostic significance in various cancers.•Lymphocyte count and percentage correlate with survival in SCLC, CRC;…”
Get full text

Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): a randomized, multicenter, phase II trial SAKK 41/07 by Helbling, D., Bodoky, G., Gautschi, O., Sun, H., Bosman, F., Gloor, B., Burkhard, R., Winterhalder, R., Madlung, A., Rauch, D., Saletti, P., Widmer, L., Borner, M., Baertschi, D., Yan, P., Benhattar, J., Leibundgut, E.O., Bougel, S., Koeberle, D.

“…We conducted a randomized, phase II, multicenter study to evaluate the anti-epidermal growth factor receptor (EGFR) mAb panitumumab (P) in combination with…”
Get full text

Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant by Molinari, F, Martin, V, Saletti, P, De Dosso, S, Spitale, A, Camponovo, A, Bordoni, A, Crippa, S, Mazzucchelli, L, Frattini, M

“…Cetuximab and panitumumab efficacy in metastatic colorectal cancer (mCRC) may be influenced by EGFR gene status and/or deregulation of its downstream…”
Get full text

Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK by Borner, M., Koeberle, D., Von Moos, R., Saletti, P., Rauch, D., Hess, V., Trojan, A., Helbling, D., Pestalozzi, B., Caspar, C., Ruhstaller, T., Roth, A., Kappeler, A., Dietrich, D., Lanz, D., Mingrone, W.

“…To determine the activity and tolerability of adding cetuximab to the oxaliplatin and capecitabine (XELOX) combination in first-line treatment of metastatic…”
Get full text

Adjuvant therapy for colon cancer: Present and perspectives by De Dosso, S, Sessa, C, Saletti, P

“…Summary Colon cancer is the second cause of death for cancer worldwide. In most cases it is diagnosed when it is still localized to the intestinal wall or in…”
Get full text

Prognostic and predictive value of TOPK stratified by KRAS and BRAF gene alterations in sporadic, hereditary and metastatic colorectal cancer patients by Zlobec, I, Molinari, F, Kovac, M, Bihl, M P, Altermatt, H J, Diebold, J, Frick, H, Germer, M, Horcic, M, Montani, M, Singer, G, Yurtsever, H, Zettl, A, Terracciano, L, Mazzucchelli, L, Saletti, P, Frattini, M, Heinimann, K, Lugli, A

“…Background: Our aim was to investigate the prognostic and predictive value of the oncogenic MAPKK-like protein T-cell-originated protein kinase (TOPK)…”
Get full text

Influence of KRAS mutations on clinical outcome in patients with curatively resected stage III colon cancer treated with adjuvant chemotherapy by De Dosso, S, Nucifora, M, Sahnane, N, Epistolio, S, Riveiro, M E, Bertolini, V, Bucci, E, Boldorini, R, Freguia, S, Frattini, M, Saletti, P

“…To profile and correlate KRAS mutations with outcome in stage III colon cancer (CC) patients who underwent adjuvant chemotherapy following curative resection…”
Get more information

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity by Borner, M. M., Bernhard, J., Dietrich, D., Popescu, R., Wernli, M., Saletti, P., Rauch, D., Herrmann, R., Koeberle, D., Honegger, H., Brauchli, P., Lanz, D., Roth, A. D.

“…Background: To determine the efficacy, impact on quality-of-life (QoL) and tolerability of two different irinotecan administration schedules in combination…”
Get full text

Chemotherapy in patients with advanced pancreatic cancer: too close to death? by Frigeri, M., De Dosso, S., Castillo-Fernandez, O., Feuerlein, K., Neuenschwander, H., Saletti, P.

“…Purpose We evaluated the attitude in using chemotherapy near the end of life in advanced pancreatic adenocarcinoma (PAC). Clinical and laboratory parameters…”
Get full text

A procedure to quantify radionuclide purity of [18F]FDG by means of gamma ray spectrometry by Calusi, S, Saletti, P, Capaccioli, L

Get full text

1322 Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in elderly patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10 by Kienle, D, Winterhalder, R, Koeberle, D, Horber, D, Kueng, M, Saletti, P, Helbling, D, Bastian, S, Dietrich, D, Baertschi, D, Pilop, C, Von Moos, R

Get full text

Temporal stability QA in functional magnetic resonance imaging by Fedeli, L, Busoni, S, Fedi, M, Saletti, P, Taddeucci, A

Get full text

Clinical and Molecular Determinants of Survival in Pancreatic Cancer Patients Treated with Second-line Chemotherapy: Results of an Italian/Swiss Multicenter Survey by MANCUSO, A, SACCHETTA, S, RECINE, F, SOLLAMI, R, LABIANCA, R, CAVALLI, F, STERNBERG, C. N, SALETTI, P. C, TRONCONI, C, MILESI, L, GARASSINO, M, MARTELLI, O, LEONE, A, ZIVI, A, CERBONE, L

“…Increased knowledge about the treatment of pancreatic cancer has influenced the management of locally advanced and metastatic disease. Nonetheless, prognosis…”
Get full text

Reply: Do we need biopsies of metastases for colorectal cancer patients? by Frattini, M, Molinari, F, Saletti, P, Mazzucchelli, L

Get full text

6589 POSTER How Much Chemotherapy Are Patients With Advanced Pancreatic Cancer Receiving at the End of Life? by Feuerlein, K, De Dosso, S, Castillo, F.O, Frigerio, M, Ghielmini, M, Saletti, P

Get full text

6015 POSTER DISCUSSION An International Consortium in Chemo-refractory Metastatic Colorectal Cancer Patients Shows Cetuximab Efficacy in Patients Harboring HER2 Gene Copy Number Gain by Martin, V, Sacconi, A, Landi, L, Riva, A, Saletti, P, Geva, R, Tejpar, S, Kalogeras, K, Frattini, M, Cappuzzo, F

Get full text